Auditor and Inspector Perspectives on Effective Control Strategies Auditor and Inspector Perspectives on Effective Control Strategies Regulatory Affairs Context The landscape of pharmaceutical and biotechnology development is increasingly complex, necessitating rigorous adherence to regulatory frameworks such as the FDA, the EMA, and the MHRA. Central to this regulatory milieu is the concept of CMC (Chemistry, Manufacturing, and Control) control strategies, which are vital in ensuring the quality, safety, and efficacy of pharmaceuticals. This article outlines critical aspects of effective control strategies, including Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs), and offers insights into regulatory expectations and best practices….

Planning validation and CMC work for PAS, CBE 30 and CBE 0 changes Planning validation and CMC work for PAS, CBE 30 and CBE 0 changes The landscape of pharmaceutical and biotech development is intricate and continuously evolving. One of the crucial aspects of this development is effectively managing Post-Approval Changes (PAC) to comply with regulatory expectations. This article serves as a comprehensive guide, designed specifically for regulatory professionals, on navigating the complexities surrounding post-approval changes, particularly focusing on the classifications of Changes Being Effected (CBE) in 30 days and CBE-0 submissions. Regulatory Context In regulatory affairs, Post-Approval Changes (PACs)…

How to classify post approval changes under FDA PAS and CBE categories How to classify post approval changes under FDA PAS and CBE categories In the dynamic landscape of pharmaceutical and biotechnology product development, regulatory affairs (RA) professionals must navigate complex regulations and guidelines governing post-approval changes. Understanding how to classify these changes under the FDA’s Post-Approval Supplement (PAS) and Changes Being Effected in 30 days (CBE-30) categories is essential for ensuring compliance, maintaining product quality, and upholding patient safety. This article serves as a comprehensive regulatory explainer manual for professionals involved in regulatory affairs, CMC, quality assurance, and technical…

Designing Data Packages to Support High Impact PAS Submissions Designing Data Packages to Support High Impact PAS Submissions Context Post-Approval Changes (PAC) represent a critical aspect of drug development, particularly in the realms of regulatory affairs (RA) and Chemistry, Manufacturing and Controls (CMC). Following a product’s approval, pharmaceutical and biopharmaceutical companies may wish to implement changes to the drug’s formulation, manufacturing process, or other critical components. Such changes can influence the product’s safety, efficacy, and quality; hence, understanding the appropriate regulatory pathways for these modifications is paramount. In the US, the Food and Drug Administration (FDA) outlines the obligations concerning…

Risk based strategies for grouping and sequencing post approval changes Risk Based Strategies for Grouping and Sequencing Post Approval Changes Context Post-approval changes (PACs) are modifications made to the product, manufacturing process, or quality parameters following a drug’s approval. These changes can occur throughout the product’s lifecycle and play a critical role in ensuring the continued safety, efficacy, and quality of pharmaceutical products. This article aims to provide a comprehensive guidance on evaluating PACs, focusing on the types of changes encompassed under the Post-Approval Supplement (PAS), Changes Being Effected in 30 Days (CBE-30), and Changes Being Effected (CBE-0) classifications as…

Managing global impact of US PAS and CBE filings on EU variations Managing global impact of US PAS and CBE filings on EU variations This article provides an in-depth exploration of the post-approval changes (PAS, CBE-30, and CBE-0) in the US regulatory landscape and their implications for EU variations. This guide is particularly relevant for regulatory affairs professionals working in the global pharmaceutical and biotech sectors, aiming to align their submission strategies across different jurisdictions. Context Post-approval changes are crucial for the ongoing lifecycle management of pharmaceuticals and biologics. These changes can range from minor alterations in manufacturing processes to…

Case studies of supplements delayed due to weak CMC justifications Case studies of supplements delayed due to weak CMC justifications Regulatory Affairs Context In the pharmaceutical and biotechnology sectors, regulatory affairs (RA) professionals play a pivotal role in navigating the complex web of regulations and guidelines that govern drug development, approval, and post-market activities. One critical area of focus is the management of post-approval changes (PACs), often categorized under supplement filings such as Prior Approval Supplements (PAS), Changes Being Effected in 30 days (CBE-30), and Changes Being Effected (CBE-0). These changes, while essential for enhancing drug products, must be communicated…

Templates for Post Approval Change Assessment and Regulatory Strategy Templates for Post Approval Change Assessment and Regulatory Strategy Context In the evolving landscape of pharmaceutics and biotechnology, post-approval changes (PAC) represent a significant aspect of lifecycle management and regulatory compliance. These changes, classified under the terms like Post Approval Supplements (PAS), Changes Being Effected in 30 Days (CBE-30), and CBE-0, require a thorough understanding of various regulatory frameworks, especially within the US (FDA), EU (EMA), and UK (MHRA) jurisdictions. This manual provides an in-depth look into the regulatory expectations, documentation strategies, and common pitfalls associated with post-approval change submissions, guiding…

Using prior knowledge and platform data in post approval change filings Using Prior Knowledge and Platform Data in Post Approval Change Filings Context In the pharmaceutical and biotechnology industries, maintaining compliance with regulatory expectations throughout the product lifecycle is crucial. Specifically, understanding the parameters surrounding post-approval changes (PAC) is essential for regulatory affairs (RA) professionals, especially when filing for augmentation or modification of existing approved products. This article will explore the intricacies of post-approval change classifications—namely, Submission Types A (PAS), Submission Types B (CBE-30), and Submission Types C (CBE-0)—within the framework of regulatory guidelines established by the US FDA, EU…

Validation considerations for post approval equipment, site and scale changes Validation considerations for post approval equipment, site and scale changes Post-approval changes (PAC) in pharmaceutical manufacturing are a critical aspect of the regulatory lifecycle of drug products. The U.S. FDA, EU EMA, and UK MHRA have clear guidelines that set the stage for how these changes should be managed, documented, and communicated to the regulatory authorities. This article serves as a comprehensive manual for regulatory affairs professionals tasked with ensuring that modifications are executed in compliance with established standards. Context of Regulatory Affairs in Post-Approval Changes In the pharmaceutical industry,…